Biotech Values

[DewDiligence]

What Are MNTA’s Goals for M118?

As shown in #msg-48837450, the phase-2a EMINENCE study found M118 to be non-inferior to unfractionated heparin (UFH) in PCI (stent implantation) in a relatively low-risk patient pool. This is nice, but MNTA is presumably expecting much more from M118 than mere non-inferiority to an existing drug.

In a larger and longer phase-2b trial, MNTA’s goal will presumably be to show that M118 is superior to a SoC comparator (UFH, Lovenox, or Angiomax) in a medium- or high-risk patient pool in ACS.

Note that ACS, rather than PCI, has always been the intended indication for M118. The phase-2a trial in PCI was run because MNTA had to do it, not because they wanted to do it (#msg-26809439).